⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TLSI News
TriSalus Life Sciences, Inc. Common Stock
Form 8-K
sec.gov
TLSI
TLSIW
TriSalus Life Sciences Announces Publication Demonstrating Enhanced Delivery and Immune Activation with Nelitolimod Delivered with Pressure-Enabled Drug Delivery in Liver Tumor Models
businesswire.com
TLSI
Form 8-K
sec.gov
TLSIW
TLSI
TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue Guidance
businesswire.com
TLSI
TriSalus Life Sciences to Host Fourth Quarter 2025 Financial Results Conference Call
businesswire.com
TLSI
Form 8-K
sec.gov
TLSI
TLSIW
TriSalus Life Sciences Announces Pricing of $40.0 Million Public Offering
businesswire.com
TLSI
TriSalus Life Sciences Announces Pricing of $40.0 Million Public Offering
businesswire.com
TLSI
TriSalus Life Sciences Proposes Public Offering
businesswire.com
TLSI
TriSalus Life Sciences Appoints Veteran Healthcare Investor Michael Stansky to its Board of Directors
businesswire.com
TLSI